التفاصيل البيبلوغرافية
| العنوان: |
Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT |
| المؤلفون: |
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo |
| المصدر: |
Liver Cancer (2024) |
| بيانات النشر: |
Karger Publishers, 2024. |
| سنة النشر: |
2024 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blinded independent imaging review (IIR) per Response Evaluation Criteria in Solid tumors version 1.1 (RECIST v1.1); per modified RECIST (mRECIST), the ORR was 40.6%. We sought to further characterize these tumor responses and explore ORR’s importance among outcomes for patients with HCC. Methods: Efficacy assessments included all patients randomized to receive lenvatinib treatment (body weight ≥60 kg, 12 mg/day; |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1664-5553 |
| Relation: |
https://beta.karger.com/Article/FullText/537947; https://doaj.org/toc/1664-5553 |
| DOI: |
10.1159/000537947 |
| URL الوصول: |
https://doaj.org/article/d6ae54a6e78a47678e598fa918d4b74a |
| رقم الانضمام: |
edsdoj.6ae54a6e78a47678e598fa918d4b74a |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder